Business
Medincell: UZEDY® Approved in South Korea Following Successful US Launch
MONTPELLIER, France, September 10, 2025--Regulatory News: Medincell (Paris:MEDCL):
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/b1e91895b67c7a6a830f26f810c1983e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LG8VobZh8P8ozq_T2fXt4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b1e91895b67c7a6a830f26f810c1983e","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Cfre4xMnet4M2UrDiP6YPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b1e91895b67c7a6a830f26f810c1983e","width":1200,"height":200}},"lazy":false},{"type":"text","content":"MONTPELLIER, France, September 10, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL):","length":24,"tagName":"p"},{"type":"text","content":"Teva Handok announced today that UZEDY®, Long-Acting Injectable Risperidone for Schizophrenia, has received regulatory approval from the South Korean Ministry of Food and Drug Safety.","length":183,"tagName":"p"},{"type":"text","content":"UZEDY® will be distributed in South Korea by Teva Handok, a joint venture between Teva, Medincell’s partner, and Handok, a leading South Korean healthcare company.","length":163,"tagName":"p"},{"type":"text","content":"Following its US approval in May 2023, UZEDY® has demonstrated strong commercial performance, reaching $117 million in net sales in 2024, and already $95 million in the first half of 2025.","length":188,"tagName":"p"},{"type":"text","content":"Medincell receives mid- to high-single digit royalties on all worldwide sales and remains eligible for up to $105 million of commercial milestones payments.","length":156,"tagName":"p"},{"type":"text","content":"Christophe Douat, CEO of Medincell said: "We are delighted to see UZEDY® receive regulatory approval in South Korea, further strengthening the strong commercial momentum observed in the United States since its launch in 2023. More patients living with schizophrenia will now be able to benefit from UZEDY® and its unique features, which position it as the treatment of choice."","length":387,"tagName":"p"},{"type":"text","content":"About Medincell","length":15,"tagName":"p"},{"type":"text","c...